抗癌药物药物化学第二版 1849条(本栏目收费,不能显示细节,电话15274084725)
8.1. G-quadruplex ligands ..... 313 313
8.2. Inhibitors of telomerase reverse transcriptase ... 316 316
8.3. Inhibitors of the RNA domain template .... 316 316
EPIGENETIC THERAPY OF CANCER ...325 325
1. Introduction .....325 325
2. Inhibitors of DNA methylation: reactivation of silenced genes ...328 328
2.1. Nucleoside inhibitors of DNA methyltransferases .... 329 329
2.2. Non-nucleoside inhibitors of DNA methyltransferase ... 335 335
3. Inhibitors of histone and other protein deacetylases ...337 337
3.1. Short-chain fatty acids ..... 339 339
3.2. Hydroxamic acids .... 340 340
3.3. Cyclic tetrapeptides ..... 343 343
3.4. Benzamides ...... 345 345
3.5. Thiols ..... 345 345
3.6. Inhibitors of HDAC4 ..... 346 346
3.7. Inhibitors of sirtuins ..... 347 347
3.8. Bromodomain inhibitors ..... 348 348
4. Regulators of histone methylation .....350 350
4.1. Inhibitors of histone methyltransferases ... 351 351
4.2. Lysine-specific demethylases (LSDs or KDMs) and their inhibitors ... 353 353
References .......356 356
ANTICANCER DRUGS TARGETING TUBULIN AND MICROTUBULES ...359 359
1. Introduction .....359 359
2. Drugs that inhibit microtubule polymerization ....361 361
2.1. Compounds binding at the vinca site ... 361 361
2.1.1. Vinca alkaloids and their synthetic analogs .... 361 361
2.1.2. Marine natural products binding at the vinca domain and their analogs . 364 364
2.2. Compounds binding at the colchicine site .... 368 368
3. Microtubule-stabilizing agents: compounds binding at the taxane site ...373 373
3.1. Taxanes ...... 373 373